TG Therapeutics reported its second quarter 2025 financial results, posting total revenue of $141.1 million, with BRIUMVI U.S. net revenue accounting for $138.8 million. The company raised its full-year 2025 guidance for BRIUMVI U.S. net product revenue to a range of $570 million to $575 million, up from the previous estimate of $560 million. Additionally, TG Therapeutics increased its total global revenue target to approximately $585 million from $575 million. Net income was reported at $28.2 million for the quarter and $33.2 million for the first six months of 2025, compared to a net income loss of $6.9 million in the prior period. Separately, Gilead Sciences announced its second quarter 2025 earnings, with total revenue rising 2% year-over-year to $7.08 billion, surpassing estimates of $6.97 billion. Adjusted earnings per share (EPS) came in at $2.01, beating the $1.98 consensus. Key product revenues included Biktarvy at $3.53 billion, Trodelvy at $364 million, and Veklury at $121 million, the latter falling short of the $200.1 million estimate. Gilead's product sales outlook for 2025 is projected between $28.30 billion and $28.70 billion, slightly below estimates of $28.73 billion.